5 Key Sessions at the Hematology and Oncology Pharmacy Association Annual Conference 2022

Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.

The annual meeting features educational sessions, symposia, and topics that pertain to pharmacists in the hematology and oncology space. The John G. Kuhn guest lecturer for the 2022 meeting is J. Bryan Sexton, PhD, who will discuss how small and practical strategies can help improve the well-being of health care workers and address mechanisms that can cause burnout, which has been a topic of conversation since the onset of the COVID-19 pandemic.

Several other key sessions Pharmacy Times will be covering include presentations in adult sarcomas, updates for the management of early-stage breast cancer, and implementations of treatment-free remission in chronic myeloid leukemia. Here are a few of the top sessions to watch for on Pharmacy Times during the conference.

• In a Pharmacy Times interview, Christy S. Harris, PharmD, BCOP, FHOPA an associate professor of Pharmacy Practice at the Massachusetts College of Pharmacy & Health Sciences, will discuss the current guidelines for therapy for adult sarcomas and address these therapies based on the tumor markers exhibited. In that, Harris will also discuss literature about how treatment location and volume of cases could affect the outcomes of treatment.
• On March 30, Jeremy Pappacena, PharmD, BCOP, clinical pharmacy specialist of Hematology and Oncology in the Allegheny Health Network, will discuss historical treatments to early-stage breast cancer and evaluate new literature around the treatment of early-stage breast cancer. Pappacena will also address monitoring plans for individuals undergoing treatment.
• On March 31, Shaily Arora, PharmD, executive regulatory science director at AstraZeneca, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, III, professor at Emory University School of Medicine, will discuss the regulatory framework for anticancer agents as well as clinical and scientific surrogate endpoints across different phases of development. They will also analyze these endpoints with points on justification, relationship to lag measures, patient preferences, and impact on development timeframes.
• Pharmacy Times interviewed outgoing HOPA President Larry Buie, PharmD, BCOP, FASHP, a clinical pharmacy manager and PGY2 adult oncology residency program director at Memorial Sloan Kettering Cancer Center, on highlights of the upcoming 2022 annual conference in Boston and to provide an overview of some of the successes and initiatives that HOPA was engaged in during his term as president.
• On April 1, Adam J. DiPippo, PharmD, BCOP clinical pharmacy specialist of leukemia at the University of Texas MD Anderson Cancer Center, and Jonathan Michael Savoy, PharmD, BCOP, clinical pharmacy specialist of leukemia at University of Texas MD Anderson Cancer Center, will be discussing the criteria for safe treatment-free remission for individuals with chronic myeloid leukemia and summarize the clinical trial data surrounding the treatment free remission. They will also address the benefits and risks as well as a monitoring plan for individuals with chronic myeloid leukemia

Stay tuned on PharmacyTimes.com for live coverage of the conference and follow Pharmacy Times on social media for the latest updates!